Ann: Expanded Heart Protection Discovery for Zantrene, page-181

Thanks for that clarification, and for the welcome. Glad to be here.

So now my question is, why would a SOC be limited to the single (coformulation) drug as opposed to the 2 drugs that make up that coformulation? We often see that inpatients in a hospital who usually take a coformulation drug end up on the separate components while in hospital, simply because they are the cheaper option.
If the answer is that the coformulation is potentially a lot safer because of the coformulation itself, and that this cannot be achieved by taking the 2 things together as separate drugs, then I understand the argument. But if it is simply a matter of a certain drug combination, then coformulation is not necessarily going to be the SOC and therefore a medico could not be held to only prescribe in that manner for fear of deviating from the SOC.

I am assuming in advance that it is the potential of the coformulation itself that is the winner here, and at present the 2 drugs are the only versions of themselves and therefore ripe to get into bed together.